GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It

2Firsts Events by 2FIRSTS Charlotte, edited by Sophia Lv
May.30.2024
GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

 

The forum began with a welcome address from GTNF founder and Executive Director of the GTNF Trust Fund, Elise Rasmussen. In her speech, Rasmussen highlighted the uncertainty in global nicotine regulation, emphasizing the volatile tobacco policies in the UK and US since the end of last year. She also expressed gratitude to the experts sharing their insights at the forum.

 

Dispelling Nicotine Myths: A "Horror" Narrative Around E-Cigarettes

 

The first keynote speech was delivered by Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School. His presentation focused on the pathological characteristics of nicotine and synthetic nicotine, detailing the molecular structure, receptors, and anatomical absorption process in the human body.

 

Professor Strupp reiterated his key point that nicotine, as a molecular structure, is not carcinogenic. He vividly compared e-cigarettes to traditional combustible cigarettes using the analogy of electric cars versus fuel cars, highlighting that the underlying logic of e-cigarettes is similar to the advantages of electric cars, which are "a cleaner process and less damage."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School

 

Following Professor Strupp's speech, James Murphy, Director of Research and Science at British American Tobacco (BAT), delivered the second keynote speech. Murphy, who previously led BAT's Group of Reduced Risk Products (PRRP) Science and was the product manager for the Americas and Sub-Saharan Africa regions, drew from his experiences in developing markets to argue that the public health community needs to adopt a consistent scientific viewpoint on new-generation tobacco products to provide regulators worldwide with accurate information and create a "stable framework."

 

In his keynote, Murphy shared his experiences and stated that the dual themes of the forum have dual significance in "promoting public health" and "focusing on social welfare."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
James Murphy, Director of Research and Science at British American Tobacco (BAT)

 

Deepening the Discussion on Nicotine and E-Cigarettes

 

The first panel discussion invited several industry experts to delve deeper into misunderstandings and myths about nicotine and e-cigarettes. The discussion was moderated by Jasjit Ahluwalia, Professor of Behavioral and Social Sciences and Professor of Medicine at Brown University School of Public Health and Alpert Medical School. The panelists included Delon Human, family doctor and president of the "Health Diplomats" group, Dave Dobbins, former COO of the American Legacy Foundation/Truth Initiative, and Sudhanshu Patwardhan, nicotine expert and health technology entrepreneur.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The first panel discussion deepened the discussion on misunderstandings and myths about nicotine and e-cigarettes

 

Ahluwalia noted that over the past decade, as the e-cigarette market has grown, the idea that "e-cigarettes are more harmful than traditional combustible cigarettes" has gained traction among smokers, leading many who had switched to e-cigarettes to return to smoking. He described this as "incredible"; the panelists agreed that the industry should invest more resources in related research to combat the "horror narrative" with science.

 

Dobbins, from a market perspective, discussed the proper direction for regulating nicotine products from the standpoint of human rights and legal principles. He argued that every adult's actions and choices are their own responsibility, and thus "adults need to be treated as adults, not managed with flavor bans or outright prohibitions on nicotine intake methods."

 

Nicotine from an Agricultural Perspective: Ensuring Farmers' Interests

 

The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers, an area less frequently highlighted by the industry. The session included George Cassels-Smith, CEO of a tobacco technology company, Ramsey S. Lewis, Professor of Plant Breeding at North Carolina State University, Carlos Pulcinelli, Global Project Manager at Alliance One International, and Lea Scott, Senior Vice President of Universal Leaf Tobacco Co.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers

 

During the discussion, the panelists analyzed the development of upstream tobacco farming from the perspectives of tobacco farmers, buyers, and regulators across the supply chain. They emphasized the critical importance of tobacco leaf quality for all stakeholders. Professor Lewis highlighted the success of developing high-quality, high-yield, disease-resistant tobacco varieties through genetic modification over the past decade. He suggested that future research and development to increase the added value of raw tobacco leaves would be a significant focus for the industry.

 

The panelists unanimously agreed that not everyone realizes that nicotine, like large-scale agriculture in livestock and crops, involves a "farm-to-table" process. Ensuring the interests of farmers who grow tobacco is essential to meet the increasing ESG (Environmental, Social, and Governance) requirements from regulators and society for nicotine companies.

 

 

About GTNF InFocus


 

InFocus is the largest online tobacco and nicotine conference. Bringing together thought leaders, industry voices, and leaf and public health experts。
 

2FIRSTS focused on the core topics and significant viewpoints of the forum, conducting in-depth interviews with government officials, business executives, and industry experts from various countries. We published over 20 high-quality reports in both text and video formats.

This series of reports not only promoted GTNF's global reach but also provided valuable information and profound insights for the high-quality development of the e-cigarette industry.

Here is an overview of key content covered by 2FIRSTS at GTNF 2023:

1. FDA CTP Director Brian King: Submitting PMTA is No Equivalent to Legal Sale
 https://www.2firsts.com/news/fda-director-brian-king-on-e-cigarette-compliance-and-tracking-systems

2. GTNF 2023: Sustainable Development and New Vape Products
https://www.2firsts.com/news/the-future-of-e-cigarettes-sustainable-development-and-new-products

3. GTNF Discusses Addressing Youth Misuse of Harm Reduction Products: A Collaborative Effort Needed
 https://www.2firsts.com/news/gtnf-discusses-addressing-youth-misuse-of-harm-reduction-products-a-collaborative-effort-needed

4. Interview with GTNF Founder: Transform Industry Through Unique Dialogues
https://www.2firsts.com/news/interview-with-gtnf-founder-transform-industry-through-unique-dialogues

Moving forward, 2FIRSTS will continue to closely track the latest developments and trends in the e-cigarette industry, committed to providing readers with cutting-edge information and in-depth analysis. This ensures that readers receive accurate and comprehensive first-hand industry updates promptly.

 

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09